Lonza is hosting a free 60-minute webinar on 25 April 2017 on how to create a compelling business case for the implementation of a paperless QC testing solution. The selection of a paperless solution is only step one of a longer capital expenditure (CAPEX) process, which can be difficult to navigate without a strong business case.
During the webinar Jeremy Tanner, Account & Business Development Representative, Lonza Bioscience Informatics, will cover:
How Value Stream Mapping (VSM) provides a useful template for collecting and visualizing the data needed
How to utilize the data collected to create a Return on Investment (ROI) summary
How to build a presentation/document for senior management to approve
Anyone interested in attending the webinar can register by selecting the following link: https://attendee.gotowebinar.com/register/1096445471066511361?source=moda-webinar-lonza-press-release
Date: Tuesday, 25 April 2017, 8 AM PDT (Los Angeles) / 11 AM EDT (New York) / 4 PM BST (London) / 5 PM CEST (Berlin)
Speaker: Jeremy Tanner, Account & Business Development Representative, Lonza Bioscience Informatics
Further information can be found on the MODA™ Paperless QC Micro Solution product page. Alternatively, by registering interest in the webinar, participants will receive a link once it is available to view the webinar "on demand" via the Lonza website.
More information about Lonza's upcoming webinars is available on the following website: www.lonza.com/qcwebinars.
Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. It harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
Not only is Lonza a custom manufacturer and developer, the company also offers services and products ranging from active pharmaceutical ingredients to drinking water sanitizers, from nutritional and personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with approximately 40 major manufacturing and R&D facilities and more than 10,000 full-time employees worldwide. The company generated sales of CHF 4.13 billion in 2016 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.
Lonza Contact Information
Lonza Cologne GmbH
Tel +49 221 991990
Fax +49 221 99199498
Lonza Group Ltd
Tel +41 61 316 8798
Fax +41 61 316 9540
Lonza Group Ltd
Tel +41 61 316 8840
Fax +41 61 316 9840
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.